Clinical, Cosmetic and Investigational Dermatology (Jul 2022)
Germinal Centre-Related Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Report of a Remission Case
Abstract
Fang Liu, Fei Qi, Xiuying Zhang, Mei Cao, Shiguang Peng Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Fang Liu, Email [email protected]: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LTs) is a rare and the most aggressive type of the cutaneous B-cell lymphoma with poor prognosis and low therapeutic response. It mostly affects elderly women, with a 5-year survival rate of 50% if not efficiently treated. We present a 28-year-old male patient with indolent PCDLBCL-LT who reached nearly 100% clearance after six rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy sessions.Keywords: primary cutaneous diffuse large B-cell lymphoma, leg type, rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), remission
